PTC Therapeutics, Inc.

Biotechnology • Healthcare • Warren, NJ, United States • PTCT (NMS)

908 222 7000 500 Warren Corporate Center Drive, Warren, NJ 07059, United States

Quarter: Q4 2025 Reported: November 4, 2025 Sentiment: Neutral

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Analysis Summary

This Form 8-K filing from PTC Therapeutics, Inc. (PTCT) on November 4, 2025, formally announces the company's financial results for the quarter ended September 30, 2025. It specifies that the full text of the press release detailing these results is furnished as Exhibit 99.1 to this report, and is incorporated by reference. Additionally, the company will host a conference call on the same day, November 4, 2025, at 4:30 p.m. eastern time, to discuss these financial outcomes and other corporate highlights. The filing itself does not contain specific financial performance metrics such as revenue, net income, or EPS, nor does it provide strategic initiatives, management commentary, forward guidance, competitive positioning, market trends, or risk factors. Its purpose is to satisfy regulatory disclosure requirements regarding the release of earnings and the scheduling of the associated investor call. Therefore, a comprehensive analysis of financial performance, strategic direction, and market outlook cannot be derived solely from this 8-K, requiring reference to the accompanying press release and the content of the conference call itself. No analyst Q&A highlights are available from this announcement.

Key Highlights

• PTC Therapeutics, Inc. announced Q4 2025 financial results.
• The quarter ended September 30, 2025.
• A conference call is scheduled for November 4, 2025, at 4:30 p.m. ET.
• Detailed financial results are available in the accompanying press release (Exhibit 99.1).

Financial Metrics

eps

N/A

YoY: N/A

revenue

N/A N/A

YoY: N/A

guidance

net income

N/A N/A

YoY: N/A

Stock Performance (90 Days)

Data through May 15, 2026

Positive Signals

• Formal announcement of earnings release indicates adherence to reporting schedule.
• Scheduled conference call provides a platform for management to communicate directly with investors.

Risks & Concerns

— Specific financial performance details and forward-looking statements are not available in this document.
— Market reaction will depend on the actual results and guidance provided in the full press release and conference call.